1. Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohn's disease.
- Author
-
Di Narzo, Antonio, Frades, Itziar, Crane, Heidi M., Crane, Paul K., Hulot, Jean-Sebastian, Kasarskis, Andrew, Hart, Amy, Argmann, Carmen, Dubinsky, Marla, Peter, Inga, and Hao, Ke
- Subjects
CROHN'S disease ,STATURE ,HEART metabolism disorders ,TYPE 2 diabetes ,MYOCARDIAL infarction ,GENETIC regulation ,INFLAMMATORY bowel diseases - Abstract
To further explore genetic links between complex traits, we developed a comprehensive framework to harmonize and integrate extensive genotype and phenotype data from the four well-characterized cohorts with the focus on cardiometabolic diseases deposited to the database of Genotypes and Phenotypes (dbGaP). We generated a series of polygenic risk scores (PRS) to investigate pleiotropic effects of loci that confer genetic risk for 19 common diseases and traits on body height, type 2 diabetes (T2D), and myocardial infarction (MI). In a meta-analysis of 20,021 subjects, we identified shared genetic determinants of Crohn's Disease (CD), a type of inflammatory bowel disease, and body height (p = 5.5 × 10
–5 ). The association of PRS-CD with height was replicated in UK Biobank (p = 1.1 × 10–5 ) and an independent cohort of 510 CD cases and controls (1.57 cm shorter height per PRS-CD interquartile increase, p = 5.0 × 10−3 and a 28% reduction in CD risk per interquartile increase in PRS-height, p = 1.1 × 10–3 , with the effect independent of CD diagnosis). A pathway analysis of the variants overlapping between PRS-height and PRS-CD detected significant enrichment of genes from the inflammatory, immune-mediated and growth factor regulation pathways. This finding supports the clinical observation of growth failure in patients with childhood-onset CD and demonstrates the value of using individual-level data from dbGaP in searching for shared genetic determinants. This information can help provide a refined insight into disease pathogenesis and may have major implications for novel therapies and drug repurposing. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF